Tonghua Dongbao Pharmaceutical Group

The company is mainly engaged in Chinese and Western patent medicines, 

biological products and plastic building materials, etc. 

It is a key high-tech enterprise of the Torch Program recognized by the Ministry of Science and Technology.

The company and its major shareholder Dongbao Group have successively developed and launched a large number of state-level new drugs and 

leading products such as "Zhennaoning", Dongbao Gantai Tablets, and Naoxuekang Tablets.

The second-phase expansion project of Dongbao genetically recombinant human insulin, 

a key national support project for the revitalization of the old industrial base in Northeast China, 

with a total investment of 350 million yuan, is intensively introducing and installing advanced foreign equipment.

The company has become one of the largest human insulin production bases in China.